Regenerative Medicine, Sun Field Clinic, TIME24 Building 1F 2-4-32 Aomi, Koto-ku, Tokyo, 135-0064, Japan.
Stem Cell Res Ther. 2020 Dec 11;11(1):538. doi: 10.1186/s13287-020-02067-x.
Arteriosclerosis is an age-related disease and a leading cause of cardiovascular disease. In animal experiments, mesenchymal stem cells and its culture-conditioned medium have been shown to be promising tools for prevention or treatment of arteriosclerosis. On the basis of these evidences, we aimed to assess whether administration of autologous adipose-derived mesenchymal stem cells (Ad-MSC) is safe and effective for treatment of arteriosclerosis.
We retrospectively reviewed clinical records of patients with arteriosclerosis who had received autologous Ad-MSC administration at our clinic. Patients' characteristics were recorded and data on lipid profile, intimal-media thickness (IMT), cardio-ankle vascular index (CAVI), and ankle-brachial index (ABI) before and after Ad-MSC administration were collected and compared.
Treatment with Ad-MSC significantly improved HDL, LDL, and remnant-like particle (RLP) cholesterol levels. No adverse effect or toxicity was observed in relation to the treatment. Of the patients with abnormal HDL values before treatment, the vast majority showed improvement in the values. Overall, the measurements after treatment were significantly increased compared with those before treatment (p < 0.01). In addition, decreases in LDL cholesterol and RLP levels were observed after treatment in patients who had abnormal LDL cholesterol or RLP levels before treatment. The majority of patients with pre-treatment abnormal CAVI values had improved values after treatment. In patients with available IMT values, a significant decrease in the IMT values was found after therapy (p < 0.01). All patients with borderline arteriosclerosis disease had improved laboratory findings after treatment. In general, post-treatment values were significantly decreased as compared with pre-treatment values. Of the patients with normal ABI values before treatment at the same time as CAVI, the vast majority remained normal after treatment.
These findings suggest that Ad-MSC administration is safe and effective in patients developing arteriosclerosis, thereby providing an attractive tool for anti-aging application.
动脉硬化是一种与年龄相关的疾病，也是心血管疾病的主要原因。动物实验表明，间充质干细胞及其培养条件培养基是预防或治疗动脉硬化的有前途的工具。基于这些证据，我们旨在评估自体脂肪来源间充质干细胞（Ad-MSC）的给药是否安全有效治疗动脉硬化。
我们回顾性地审查了在我们诊所接受自体 Ad-MSC 给药治疗的动脉硬化患者的临床记录。记录患者特征，并收集和比较给药前后血脂谱、内膜中层厚度（IMT）、心踝血管指数（CAVI）和踝臂指数（ABI）的数据。
Ad-MSC 治疗可显著改善 HDL、LDL 和残粒样颗粒（RLP）胆固醇水平。治疗过程中未观察到不良反应或毒性。在治疗前 HDL 值异常的患者中，绝大多数患者的 HDL 值均有所改善。总体而言，治疗后的测量值明显高于治疗前（p<0.01）。此外，在治疗前 LDL 胆固醇或 RLP 水平异常的患者中，治疗后 LDL 胆固醇和 RLP 水平下降。大多数治疗前 CAVI 值异常的患者治疗后 CAVI 值有所改善。在 IMT 值可用的患者中，治疗后 IMT 值显著降低（p<0.01）。所有患有边缘性动脉硬化疾病的患者治疗后实验室检查结果均有所改善。一般来说，与治疗前相比，治疗后值明显降低。在治疗前与 CAVI 同时具有正常 ABI 值的患者中，绝大多数患者在治疗后仍保持正常。
这些发现表明，Ad-MSC 给药在发生动脉硬化的患者中是安全有效的，因此为抗衰老应用提供了一种有吸引力的工具。
